Detalles de la búsqueda
1.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Lancet Oncol
; 24(3): 213-227, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36796394
2.
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Br J Haematol
; 201(2): 267-279, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36541152
3.
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Blood
; 136(9): 1091-1104, 2020 08 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32438407
4.
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial.
Haematologica
; 107(1): 231-242, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33297668
5.
Long-term outcomes of image-guided ablation and laparoscopic partial nephrectomy for T1 renal cell carcinoma.
Eur Radiol
; 32(9): 5811-5820, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35384457
6.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33428632
7.
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Br J Haematol
; 193(3): 551-555, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32524584
8.
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Br J Haematol
; 192(5): 853-868, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32656799
9.
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Haematologica
; 106(7): 1957-1967, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32499244
10.
SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection.
Eur Respir J
; 56(5)2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32616595
11.
Subclonal TP53 copy number is associated with prognosis in multiple myeloma.
Blood
; 132(23): 2465-2469, 2018 12 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373884
12.
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.
Hum Genomics
; 13(1): 37, 2019 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31429796
13.
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(1): 57-73, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30559051
14.
Neutral tumor evolution in myeloma is associated with poor prognosis.
Blood
; 130(14): 1639-1643, 2017 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28827410
15.
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Haematologica
; 104(7): 1440-1450, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30733268
16.
Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.
Br J Haematol
; 182(6): 816-829, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29984830
17.
High hospital research participation and improved colorectal cancer survival outcomes: a population-based study.
Gut
; 66(1): 89-96, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27797935
18.
Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
Lancet Oncol
; 18(11): 1543-1552, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29037984
19.
Active multiple myeloma suppresses and typically eliminates coexisting MGUS.
Br J Cancer
; 117(6): 835-839, 2017 Sep 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28728165
20.
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
Br J Haematol
; 176(4): 573-582, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28032335